NEW YORK – MammaPrint, a breast cancer recurrence test sold by Amsterdam-headquartered Agendia, cut healthcare costs in five out of six countries evaluated and was cost-effective in all six, according to an analysis published in the latest issue of the European Journal of Cancer.